Phase 1/2 × Recruiting × Carcinoma, Non-Small-Cell Lung × Clear all A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Phase 1/2 Recruiting
398 enrolled
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Phase 1/2 Recruiting
594 enrolled
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Phase 1/2 Recruiting
150 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/2 Recruiting
126 enrolled
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Phase 1/2 Recruiting
191 enrolled
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Phase 1/2 Recruiting
37 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Phase 1/2 Recruiting
252 enrolled
KaRAnaSa
Phase 1/2 Recruiting
60 enrolled
Alectinib Pharmacokinetic in Patients With NSCLC
Phase 1/2 Recruiting
45 enrolled
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
Phase 1/2 Recruiting
56 enrolled
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Phase 1/2 Recruiting
162 enrolled
RAINFOL-01
Phase 1/2 Recruiting
764 enrolled
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
1,000 enrolled
TRIDENT-1
Phase 1/2 Recruiting
500 enrolled 5 FDA
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Phase 1/2 Recruiting
342 enrolled
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/2 Recruiting
295 enrolled
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Phase 1/2 Recruiting
250 enrolled
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Phase 1/2 Recruiting
428 enrolled
TD-ENSEMBLE
Phase 1/2 Recruiting
20 enrolled
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/2 Recruiting
159 enrolled
ALTAIR
Phase 1/2 Recruiting
152 enrolled
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Phase 1/2 Recruiting
370 enrolled
Agni-01
Phase 1/2 Recruiting
208 enrolled
BetaBart
Phase 1/2 Recruiting
61 enrolled
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
Phase 1/2 Recruiting
170 enrolled
KRAScendo 170
Phase 1/2 Recruiting
320 enrolled
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
Phase 1/2 Recruiting
231 enrolled
SYNERGY-101
Phase 1/2 Recruiting
364 enrolled
PROSPER
Phase 1/2 Recruiting
403 enrolled
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
416 enrolled
A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors
Phase 1/2 Recruiting
370 enrolled
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
60 enrolled
MK-3475-01A
Phase 1/2 Recruiting
450 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Phase 1/2 Recruiting
182 enrolled
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/2 Recruiting
300 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Phase 1/2 Recruiting
980 enrolled
DUO-NK-NSCLC
Phase 1/2 Recruiting
48 enrolled
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Phase 1/2 Recruiting
616 enrolled
NAPISTAR1-01
Phase 1/2 Recruiting
250 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Phase 1/2 Recruiting
180 enrolled
SMP-3124LP in Adults With Advanced Solid Tumors
Phase 1/2 Recruiting
120 enrolled
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Phase 1/2 Recruiting
252 enrolled
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Phase 1/2 Recruiting
251 enrolled
EVEREST-2
Phase 1/2 Recruiting
474 enrolled
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Phase 1/2 Recruiting
159 enrolled
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
150 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled